Related Experiment Video
Updated: Jan 1, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis
Hee Kyung Kim1,2, Inkyoung Lee3, Seung Tae Kim1
1Division of Hematology-Oncology, Departments of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract:
The role of Ras-related associated with diabetes (RRAD) in gastric cancer (GC) or colorectal cancer (CRC) has not been investigated. We aimed to investigate the biological and clinical roles of RRAD in GC and CRC and to assess RRAD as a therapeutic target. A total of 31 cancer cell lines (17 GC cell lines, 14 CRC cell lines), 59 patient-derived cells (PDCs from 48 GC patients and 11 CRC patients), and 84 matched pairs of primary cancer tissue and non-tumor tissue were used to evaluate the role of RRAD in vitro and in vivo. RRAD expression was frequently increased in GC and CRC cell lines, and siRNA/shRNA-mediated RRAD inhibition induced significant decline of tumor cell proliferation both in vitro and in vivo. A synergistic effect of RRAD inhibition was generated by combined treatment with chemotherapy. Notably, RRAD expression was markedly increased in PDCs, and RRAD inhibition suppressed PDC proliferation. RRAD inhibition also resulted in reduced cell invasion, decreased expression of EMT markers, and decreased angiogenesis and levels of associated proteins including VEGF and ANGP2. Our study suggests that RRAD could be a novel therapeutic target for treatment of GC and CRC, especially in patients with peritoneal seeding.
Insights
Ras-related associated with diabetes (RRAD) is elevated in gastric cancer (GC) and colorectal cancer (CRC). Inhibiting RRAD suppressed tumor growth and invasion, suggesting it as a potential therapeutic target for GC and CRC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The role of Ras-related associated with diabetes (RRAD) in gastric cancer (GC) and colorectal cancer (CRC) remains unexplored.
- RRAD's involvement in cancer pathogenesis warrants investigation as a potential therapeutic target.
Purpose of the Study:
- To investigate the biological and clinical significance of RRAD in GC and CRC.
- To evaluate RRAD as a potential therapeutic target for these cancers.
Main Methods:
- Analysis of RRAD expression in GC and CRC cell lines, patient-derived cells (PDCs), and matched tumor/non-tumor tissues.
- In vitro and in vivo experiments involving siRNA/shRNA-mediated RRAD inhibition.
- Assessment of RRAD inhibition's effects on cell proliferation, invasion, EMT markers, and angiogenesis.
Main Results:
- RRAD expression was frequently upregulated in GC and CRC cell lines and PDCs.
- RRAD inhibition significantly reduced tumor cell proliferation both in vitro and in vivo.
- Combined RRAD inhibition with chemotherapy showed synergistic effects.
- RRAD inhibition decreased cell invasion, EMT marker expression, and angiogenesis, including VEGF and ANGP2 levels.
Conclusions:
- RRAD is frequently overexpressed in GC and CRC and drives tumor progression.
- RRAD inhibition demonstrates anti-cancer effects, including reduced proliferation and invasion.
- RRAD represents a promising novel therapeutic target for GC and CRC, particularly for patients with peritoneal seeding.
